Literature DB >> 33842275

Rotational intraperitoneal pressurized aerosol chemotherapy in a porcine model.

Jaehee Mun1, Soo Jin Park1, Hee Seung Kim1.   

Abstract

Peritoneal carcinomatosis (PC) commonly represent drug resistance to intravenous (IV) chemotherapy in advanced or recurrent disease of solid tumors. For improving the prognosis of PC, intraperitoneal (IP) chemotherapy has been introduced in the clinical setting, and phase III trials proved the superiority of IP chemotherapy to IV chemotherapy, in particular, in advanced ovarian cancer. However, increased toxicities by IP chemotherapy lead to reduced cycles of chemotherapy, which does not guarantee its effectiveness. Moreover, hyperthermic IP chemotherapy after cytoreductive surgery also showed improved survival compared to IV chemotherapy in advanced ovarian cancer. Nevertheless, limited distribution and diffusion of drugs, and grade 3 or 4 renal and hepatic toxicity of 20% preclude the expansion of its application. On the other hand, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is known to show the effect by delivering drugs to the parietal and visceral peritoneum in the form of aerosol under the abdominal pressure of 12 mmHg induced by laparoscopic system. Although low dose equivalent to about 1% dose of resistant drugs for IV chemotherapy and normothermia are used in PIPAC, it may improve tumor response and quality of life by repetitive application of PIPAC due to the increased distribution and penetration depth of drugs. However, the heterogeneous distribution of drugs is still the major limitation of PIPAC because the nozzle is placed at the possible outlying position to the tumor-bearing tissues during laparoscopic surgery. Therefore, we developed a novel prototype for PIPAC, rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) system because rotation of the nozzle and change of spray direction can contribute to homogenous distribution of drugs, and compared the distribution of drugs between PIPAC and RIPAC in a porcine model mimicking human body. As a result, RIPAC was more effective than PIPAC in terms of the distribution of drugs into the visceral and parietal peritoneum. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Rotational; aerosol; chemotherapy; intraperitoneal (IP); pressurized

Year:  2021        PMID: 33842275      PMCID: PMC8033043          DOI: 10.21037/gs-2019-ursoc-11

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  18 in total

1.  Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Joan L Walker; Deborah K Armstrong; Helen Q Huang; Jeffrey Fowler; Kenneth Webster; Robert A Burger; Daniel Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2006-01       Impact factor: 5.482

2.  Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Daniel Göhler; Veria Khosrawipour; Tanja Khosrawipour; David Diaz-Carballo; Thomas Albert Falkenstein; Jürgen Zieren; Michael Stintz; Urs Giger-Pabst
Journal:  Surg Endosc       Date:  2016-09-08       Impact factor: 4.584

3.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model.

Authors:  Veria Khosrawipour; Tanja Khosrawipour; Alexander Jens Peter Kern; Aras Osma; Burak Kabakci; David Diaz-Carballo; Eckart Förster; Jürgen Zieren; Khashayar Fakhrian
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-02       Impact factor: 4.553

5.  Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.

Authors:  Clemens B Tempfer; Guido Winnekendonk; Wiebke Solass; Reinhard Horvat; Urs Giger-Pabst; Juergen Zieren; Guenther A Rezniczek; Marc-André Reymond
Journal:  Gynecol Oncol       Date:  2015-02-18       Impact factor: 5.482

6.  A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.

Authors:  M A Steller; M J Egorin; E L Trimble; D L Bartlett; E G Zuhowski; H R Alexander; R L Dedrick
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study.

Authors:  Clemens B Tempfer; Günther A Rezniczek; Paula Ende; Wiebke Solass; Marc-André Reymond
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

8.  Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.

Authors:  Florian Struller; Philipp Horvath; Wiebke Solass; Frank-Jürgen Weinreich; Dirk Strumberg; Marios K Kokkalis; Imma Fischer; Christoph Meisner; Alfred Königsrainer; Marc A Reymond
Journal:  Ther Adv Med Oncol       Date:  2019-05-13       Impact factor: 8.168

9.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

10.  Evaluation of a Novel Prototype for Pressurized Intraperitoneal Aerosol Chemotherapy.

Authors:  Hee Su Lee; Junsik Kim; Eun Ji Lee; Soo Jin Park; Jaehee Mun; Haerin Paik; Soo Hyun Oh; Sunwoo Park; Soomin Ryu; Whasun Lim; Gwonhwa Song; Hee Seung Kim; Jung Chan Lee
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

View more
  3 in total

1.  Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model.

Authors:  Soo Jin Park; Eun Ji Lee; Aeran Seol; Sunwoo Park; Jiyeon Ham; Ga Won Yim; Seung-Hyuk Shim; Whasun Lim; Suk-Joon Chang; Gwonhwa Song; Ji Won Park; Hee Seung Kim
Journal:  J Gynecol Oncol       Date:  2022-05-24       Impact factor: 4.756

2.  Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol generator (usPIPAC).

Authors:  Phil Höltzcke; Iaroslav Sautkin; Samuel Clere; Arianna Castagna; Alfred Königsrainer; Peter P Pott; Marc A Reymond
Journal:  Surg Endosc       Date:  2022-08-29       Impact factor: 3.453

3.  Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum.

Authors:  Soo Jin Park; Eun Ji Lee; Hee Su Lee; Junsik Kim; Sunwoo Park; Jiyeon Ham; Jaehee Mun; Haerin Paik; Hyunji Lim; Aeran Seol; Ga Won Yim; Seung-Hyuk Shim; Beong-Cheol Kang; Suk Joon Chang; Whasun Lim; Gwonhwa Song; Jae-Weon Kim; Nara Lee; Ji Won Park; Jung Chan Lee; Hee Seung Kim
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.